MLYS (Mineralys Therapeutics) Net Margin %: 0.00% (As of Mar. 2026)


MLYS Mineralys Therapeutics Inc MLYS
37 GF Score
Price $30.40
! 2 Warning Signs
View Full Analysis

What is Mineralys Therapeutics Net Margin %?

Mineralys Therapeutics MLYS -0.16% 37 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates MLYS with a GF Score™ of 37/100. The stock has 2 warning signs investors should review. Among 937 Biotechnology companies, Mineralys Therapeutics ranks worse than 106723.48% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Mineralys Therapeutics's Net Income for the three months ended in Mar. 2026 was $-39.34 Mil. Mineralys Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Mineralys Therapeutics's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Mineralys Therapeutics's Net Margin % or its related term are showing as below:


MLYS's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.29
* Ranked among companies with meaningful Net Margin % only.

Mineralys Therapeutics  (NAS:MLYS) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Mineralys Therapeutics Net Margin % Related Terms

Mineralys Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Mineralys Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mineralys Therapeutics Net Margin % Chart

Mineralys Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Mineralys Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MLYS vs VCEL, NRIX, PHVS: Net Margin % Comparison

For the Biotechnology subindustry, Mineralys Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mineralys Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mineralys Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Mineralys Therapeutics's Net Margin % falls into.


MLYS
37GF Score
Mineralys Therapeutics Inc MLYS
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mineralys Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Mineralys Therapeutics's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-154.651/0
= %

Mineralys Therapeutics's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-39.339/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Mineralys Therapeutics (MLYS) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Mineralys Therapeutics and its competitors. According to the industry distribution chart, Mineralys Therapeutics ranks #999999 out of 937 companies in the Biotechnology industry.
Is Mineralys Therapeutics' Net Margin % too high?
Mineralys Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, Mineralys Therapeutics ranks #999999 out of 937 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Mineralys Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Mineralys Therapeutics' Net Margin % compare to VCEL and NRIX?
According to the Biotechnology industry distribution chart, Mineralys Therapeutics ranks #999999 out of 937 companies for Net Margin %. This places Mineralys Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Mineralys Therapeutics and its competitors. Mineralys Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mineralys Therapeutics stock overvalued right now?
Mineralys Therapeutics (MLYS) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Mineralys Therapeutics' overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Mineralys Therapeutics (MLYS), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mineralys Therapeutics Business Description

Address 150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
37GF Score

Get the complete analysis for MLYS

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$30.40
Price